While there is no known cure for breast cancer, scientists are working on medicines that could be key to treating the disease, according to a new report.
»RELATED: What new breast cancer study means for patients with chemo
Mayo Clinic researchers recently conducted a study to develop a vaccine that could eliminate cancer cells and possible disease recurrence.
The vaccine helps the body withstand the return of the human epidermal growth factor receptor 2 (HER2), a protein that can cause breast cancer. It should be used with trastuzumab, an immunostimulating drug given to women after HER2 tumor removal. If the researchers are successful, they believe the vaccine could prevent the cancer from returning to other parts of the body and spreading
Here's how it works:
The vaccine in combination with trastuzumab works by activating the B- Immune system cells that attack breast tumor cells with HER2. The process then triggers other cell groups to promote resistance to disease recurrence.
»RELATED: Breast cancer treatment may trigger heart problems, says study
"The vaccine offers a prevention strategy to avert cancer reform," co-author Keith Knutson said in a statement. "The body's T-cells and B-cells synergize with each other for a strong, lasting immune response."
The analysts found that the drug can cause mild reactions such as fatigue. For future research, they hope to find out how long immunity will last and whether it can be used to target other cancer cells.
"The standard approaches to treating cancer address the existing disease," Knutson said. "Our goal is to develop a strategy to handle recurrences, we have good medicines like trastuzumab that can disrupt the recurrence of HER2 breast cancer and we hope that a vaccine that tackles multiple aspects of the body's immune system, build on these achievements. "
The researchers have received a US $ 1
»RELATED: Avoid this meat to prevent breast cancer, says study